Insulin Action in Individuals With Type 2 Diabetes by Natural Fatty Acids or the Medication Pioglitazone

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the changes in insulin (a hormone produced in the body by the pancreas that regulates the amount of sugar in the blood) action and adiponectin (a protein hormone which regulates sugar levels and fatty acid breakdown) levels after giving individuals with type 2 diabetes a medication, pioglitazone, for three weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Albert Einstein College of Medicine; Albert Einstein College of Medicine of Yeshiva University
• Collaborator: Takeda
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Individuals with Type 2 Diabetes

• HbA1c over 8%

Exclusion Criteria:

• Individuals with bleeding disorders including GERD, PUD, any GI bleeding

• High blood pressure

• History of Coronary Artery Disease or exertional chest pain